drugset
drugset / Trial / NCT06139315

A Study to Test How Well Different Doses of BI 765845 Are Tolerated by Healthy People

NCT06139315 ↗

Phase 1 Completed 92 enrolled Boehringer Ingelheim
RandomizedParallel-groupSingle-blindTreatment

Summary

The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics (PK) of BI 765845 in healthy male subjects and female subjects of non-childbearing potential following intravenous administration of single rising doses.

Timeline

Start
2022-06-02
Primary completion
2023-06-07
Completion
2023-06-07

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 765845 Unknown — Intravenous

Indications

No indication recorded.